Advertisement
Screener

FATE THERAPEUTICS INC (FATE) Operating Lease, Weighted Average Discount Rate, Percent

2.8 / 5 stars · 68/120 Roast Me

FATE THERAPEUTICS INC Operating Lease, Weighted Average Discount Rate, Percent

FATE THERAPEUTICS INC (FATE) had Operating Lease, Weighted Average Discount Rate, Percent of 8.50% as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Notes › Leases

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-13

  • 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 8.50%.
  • 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 8.50%.
  • 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 8.50%.
  • 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 8.40%.
Period endOperating Lease, Weighted Average Discount Rate, Percent
2026-06-308.50%
10-Q · filed 2026-08-13
2026-03-318.50%
10-Q · filed 2026-05-13
2025-12-318.50%
10-K · filed 2026-02-26
2025-09-308.40%
10-Q · filed 2025-11-13
2025-06-308.40%
10-Q · filed 2025-08-12
2025-03-318.40%
10-Q · filed 2025-05-13
2024-12-318.40%
10-K · filed 2025-03-05
2024-09-308.40%
10-Q · filed 2024-11-12
2024-06-308.35%
10-Q · filed 2024-08-13
2024-03-318.35%
10-Q · filed 2024-05-09
2023-12-318.34%
10-K · filed 2024-02-26
2023-09-308.34%
10-Q · filed 2023-11-08
2023-06-308.34%
10-Q · filed 2023-08-08
2023-03-318.29%
10-Q · filed 2023-05-03
2022-12-318.28%
10-K · filed 2023-02-28
2022-09-308.28%
10-Q · filed 2022-11-03
2022-06-308.19%
10-Q · filed 2022-08-03
2022-03-316.90%
10-Q · filed 2022-05-04
2021-12-316.94%
10-K · filed 2022-02-28
2021-09-308.40%
10-Q · filed 2021-11-04
2021-06-308.40%
10-Q · filed 2021-08-04
2021-03-318.40%
10-Q · filed 2021-05-05
2020-12-318.40%
10-K · filed 2021-02-24
2020-09-308.40%
10-Q · filed 2020-11-05
2020-06-308.40%
10-Q · filed 2020-08-05
2020-03-318.40%
10-Q · filed 2020-05-11
2019-12-318.00%
10-K · filed 2020-03-02
2019-09-308.00%
10-Q · filed 2019-11-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35